Voriconazole: A broad-spectrum triazole for the treatment of invasive fungal infections

Expert Review of Hematology

Volumn 2, Issue 3, 2009, Pages 237-254

  Cecil, Jane A ^a   Wenzel, Richard P ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal treatment; Aspergillus; Azole; Candida; Ergosterol synthesis; Fungi; Fusarium; Lanosterol 4 demethylase; Mold; Mycoses; Pheohyphomycosis; Scedosporium; Triazole; Voriconazole; Yeast; Zygomycosis

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CLOTRIMAZOLE; CYCLOSPORIN; ERGOT ALKALOID; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; PHENYTOIN; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TERFENADINE; TRIAZOLE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; AUDITORY HALLUCINATION; BRAIN DISEASE; CANDIDEMIA; CANDIDIASIS; CHILL; COST CONTROL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; ERYTHEMA MULTIFORME; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEVER; FUSARIUM; HALLUCINATION; HEADACHE; HEART ATRIUM FIBRILLATION; HEPATITIS; HUMAN; INVASIVE CANDIDIASIS; JAUNDICE; KIDNEY DISEASE; LEUKOCYTOSIS; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG ASPERGILLOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; PANCREATITIS; PARESTHESIA; PHOTOSENSITIZATION; PRIORITY JOURNAL; PSEUDOPORPHYRIA; QT PROLONGATION; RASH; REVIEW; SCEDOSPORIUM APIOSPERMUM; SIDE EFFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; HUMANS; MYCOSES; PYRIMIDINES; TRIAZOLES;

EID: 77953381993     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.13     Document Type: Review

References (111)

1. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin. Infect. Dis. 17, S487-S491 (1993).
2. Pannuti C, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer 69(11), 2653-2662 (1992).
3. McNeil MM, Nash SL, Haijeh RA et al.. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33(5), 641-647 (2001).
4. Nucci M, Marr KA. Emerging fungal diseases. Clin. Infect. Dis. 41(4), 521-526 (2005).
5. Richardson MD. Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother. 56(Suppl. 1), i5-i11 (2005).
6. Pappas PG, Rex JH, Lee J et al.. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37(5), 634-643 (2003).
7. Kontoyiannis DP, Torres HA, Chagua M et al.. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand. J. Infect. Dis. 36(8), 564-569 (2004).
8. Pinner RW, Teutsch SM, Simonsen L et al.. Trends in infectious mortality in the United States. JAMA 275(3), 189-193 (1996).
9. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32(3), 358-366 (2001).
10. Rabkin JM, Oroloff SL, Corless CL et al.. Association of fungal infection and increased mortality in liver transplant recipients. Am. J. Surg. 179, 426-430 (2000).
11. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100, 4358-4366 (2002).
12. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin. Infect. Dis. 39, 588-590 (2004).
13. Nucci M, Marr KA, Queiroz-Telles F et al.. Fusarium infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 38, 1237-1242 (2004).
14. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin. Infect. Dis. 34, 467-476 (2002).
15. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr. Opin. Infect. Dis. 16(6), 607-612 (2003).
16. Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J. Clin. Microbiol. 41(12), 5525-5529 (2003).
17. Procop GW, Roberts GD. Emerging fungal diseases: the importance of the host. Clin. Lab. Med. 24(3), 691-719 vi-vii (2004).
18. Imhof A, Balajee SA, Fredericks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39(5), 743-746 (2004).
19. Siwek, GT, Dodgson KJ, Magalhaes- Silverman M et al.. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis. 39(4), 584-587 (2004).
20. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis during voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 350(9), 950-952 (2004).
21. Kobayashi K, Kami M, Murashige N, Kishi Y, Fujisaki G, Mitamura T. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica 89(11), ECR 42 (2004).
22. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP et al.. Infections due to Aspergillus terrreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis. 39(2), 192-198 (2004).
23. Patterson TF, Kirkpatrick WR, White M et al.. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 79(4), 250-260 (2000).
24. Wingard JR, Kubilis P, Lee L et al.. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29(6), 1402-1407 (1999).
25. Bates DW, Su L, Yu DT et al.. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 33(6) 915-916 (2001).
26. Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl. Infect. Dis. 1(4), 272-283 (1999).
27. Denning DW. Invasive aspergillosis. Clin. Infect. Dis. 26(4), 781-803 (1998).
28. Bowden R, Chandrasekar P, White M et al.. A double blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35(4), 359 (2002).
29. Cornely OA, Maertens J, Bresnik M et al.. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high loading dose regimen with standard dosing (AmBiload Trial). Clin. Infect. Dis. 44(10), 1289-1297 (2007).
30. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother. 42, 3018-3021 (1998).
31. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-104,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40, 1948-1949 (1996).
32. Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn. Microbiol. Infect. Dis. 31, 297-300 (1998).
33. Pfaller MA, Diekema DJ, Jones RN et al.. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilties to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39, 3254-3259 (2001).
34. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41, 575-577 (1997).
35. Oakley KL, Moore CB, Denning DW. In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J. Antimicrob. Chemother. 42, 91-94 (1998).
36. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar DH. A comparative study of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH-56592). Antimicrob. Chemother. 46, 229-234 (2000).
37. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17, 573-575 (1998).
38. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J. Clin. Microbiol. 37, 3946-3951 (1999).
39. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiacious fungi. J. Clin. Microbiol. 39, 954-958 (2001).
40. Cuenca-Estrella M, Ryiz-Diez B, Martinez-Suarez JV, Monzon A, Rodriguez-Tudela JL. Comparative in vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother. 43, 149-151 (1999).
41. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45, 2151-2153 (2001).
42. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,456) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36, 198-202 (1998).
43. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomycosis dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. 44, 1734-1736 (2000).
44. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J. Antimicrob. Chemother. 61(Suppl. 1), i19-i30 (2008).
45. Kauffman CA, Carver PL. Update on echinocandins. Semin. Respir. Crit. Care Med. 29, 211-219 (2008).
46. Fritz JM, Brielmaier BD, Dubberke ER. Micafungin for the prophylaxis and treatment of Candida infections. Expert Rev. Anti. Infect. Ther. 6(2), 153-162 (2008).
47. Sanati H, Belanger P, Fratti B, Ghannoum M. A new triazole voriconazole (UK-109,496) blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob. Agents Chemother. 41, 2492-2496 (1997).
48. Hoban DJ, Zhanel GC, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob. Agents Chemother. 43, 1463-1464 (1999).
49. Pfaller MA, Zhang J, Messer SA et al.. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43, 169-171 (1999).
50. Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole, and voriconazole. J. Antimicrob. Chemother. 48, 919-921 (2001).
51. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46, 2546-2553 (2002).
52. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin. Invest. Drugs 11, 409-429 (2002).
53. Walsh TJ, Mats OK, Driscoll T et al.. Pharmacokinetics and safety of intravenous voriconazole in children after single or multiple dose administration. Antimicrob. Agents Chemother. 48(6), 2166-2172 (2004).
54. Walsh TJ, Lutsar I, Driscoll T et al.. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21, 240-248 (2002).
55. Lazarus HM, Blumer JL, Yanovicjh S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin, Pharmacol. 42, 395-402 (2002).
56. Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy 23, 1441 (2003).
57. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46(2), 201-211 (2008).
58. Desta Z, Zhao X, Shin J, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinetics 41(12), 913-958 (2002).
59. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630-637 (2003).
60. Denning DW, Ribaud P, Milpied N et al.. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34, 563-571 (2002).
61. Herbrecht R, Denning DW, Patterson TF et al.. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347 (6), 408-415 (2002). (Pubitemid 34851833)
62. Wenzel R, Del Farero A, Kibbler C et al.. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J. Antimicrob. Chemother. 55, 352-361 (2005).
63. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am. J. Med. 119(6), e17-e24 (2006).
64. Baden LR, Katz JT, Fishman JA et al.. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 76(11), 1632-1637 (2003).
65. Husain S, Paterson DL, Studer S et al.. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant. 6(12), 3008-3016 (2006). (Pubitemid 44777932)
66. Camuset J, Nunes H, Dombret MC et al.. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 131(5), 1435-1441 (2007).
67. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J. Infect. 52(5), e133-e137 (2006).
68. Walsh TJ, Pappas P, Winston DJ et al.. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346, 225-234 (2002). (Pubitemid 34438861)
69. Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever [letter]. N. Engl. J. Med. 346, 289-290 (2002).
70. Ullman AJ, Heussel CP, Cornerly OA. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy [letter]. N. Engl. J. Med. 346, 1745-1747 (2002).
71. Walsh TJ, Lee J, Dismukes WE. Decisions about voriconazole versus liposomal amphotericin B [letter]. N. Engl. J. Med. 346, 1499 (2002).
72. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 22(11), 651-655 (2003).
73. Kullberg B, Sobel J, Ruhnke M et al.. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366(9), 1435-1442 (2005).
74. Ally R, Schurmann D, Kreisel W et al.. A randomized, double blind, double dummy multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33, 1447-1454 (2001).
75. Hegener P, Troke P, Fatkenheuer G, Diehl V, Ruhnke M. Treament of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12, 2227-2228 (1998).
76. Marr KA, Carter RA, Cripper F, Wald A, Corey L. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 909-917 (2002). (Pubitemid 34229758)
77. Diekema DJ, Messer SA, Hollis RA, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41(3), 3623-3626 (2003).
78. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lustar I Voriconazole for the treatment of S. apiospermum and S. prolificans infection. Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America. New Orleans, LA, USA, 7-10 September 2000 (Abstract 305).
79. Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 46(5-6), 233-236 (2003).
80. Studahl M, Backteman T, Stalhammar F, Chryssanthou E, Petrini B. Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery. Acta Paediatr. 92(8), 980-982 (2003).
81. Nesky MA, McDougal EC, Peacock JE Jr. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin. Infect. Dis. 31, 673-677 (2000).
82. Munoz P, Marin M, Tornero P et al.. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin. Infect. Dis. 31, 1499-1501 (2000).
83. Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J. Clin. Microbiol. 36, 1436-1438 (1998).
84. Poza G, Montoya J, Redondo C et al.. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin. Infect. Dis. 30, 981-982 (2000).
85. Jabado N, Casanova J-L, Haddad E et al.. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin. Infect. Dis. 27, 1437-1441 (1998).
86. Hernandez Prats C, Llinares Tello F, Burgos San Jose A, Selva Otaolaurruchi J, Ordovas Baines JP. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann. Pharmacother. 38(3), 414-417 (2004).
87. Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br. J. Ophthamol. 84, 932-933 (2000).
88. Vincent AL, Cabrero JE, Greene JN et al.. Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient. Cancer Control 10(5), 414-419 (2003).
89. Friese G, Discher T, Fussle R, Schmalreck A, Lohmeyer J. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 15, 2344-2345 (2001).
90. Perfect JR, Marr KA, Walsh TJ et al.. Voriconazole for less common emerging or refractory fungal infections. Clin. Infect. Dis. 36, 1122-1131 (2003).
91. Hillmarsdottir J, Thorsteinsson SB, Asmundsson P et al.. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scan. J. Infect. Dis. 32, 331-331 (2000).
92. Smith J, Safdar N, Knasinski V et al.. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50, 1570 (2006).
93. Trifilio S, Ortiz R, Pennich G et al.. Voriconazole drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35, 509 (2005).
94. Trifilio S, Pennick G, Pi J et al.. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109(8), 1532-1535 (2007).
95. Kirkpatrick WR, Perea S, Coco BJ et al.. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46, 2564-2568 (2002).
96. Petraitis V, Petraitiene R, Sarafandi AA et al.. Combination therapy in treatment of experimental pulmonary aspergillosis; synergistic interaction between antifungal triazole and an echinocandin. J. Infect. Dis 187, 1831-1833 (2003).
97. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39, 797-802 (2004).
98. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44(4), 531-540 (2007).
99. Diekema DJ, Messer SA, Hollis RJ et al.. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 63(2), 233-236 (2009).
100. Pfaller MA, Messer SA, Boyken L et al.. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46(8), 2568-2572 (2008).
101. Verweij PE, Mellado E, Melchers WJG. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356(14), 1481-1483 (2007).
102. Tomaszewski K, Purkins L. Visual effects with voriconazole. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16-19 December 2001 (Abstract A639).
103. Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin. Infect. Dis. 47, e7-e10 (2008).
104. Huang DB, Wu JJ, Lahart CJ. Toxic epidermal necrolysis as a complication of treatment with voriconazole. South. Med. J. 97(11), 1116-1117 (2004).
105. Curigliano G, Formica V, DePas G et al.. Life threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. Ann. Oncol. 17, 1174-1175 (2006).
106. Vishnubhotla P, Ibrahim RB, Abidi MH et al.. Fever and eosinophilia associated with voriconazole. Ann. Pharmacother. 38, 900 (2004).
107. Tolland JP, McKeown PP, Corbett JR. Voriconazole-induced pseudoporphyria. Photodermatol. Photoimmunol. Photomed. 23(1), 29-31 (2007).
108. Trifilio SM, Bennett CL,Yarnold PR et al.. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem cell transplants or intensive chemotherapy. Bone Marrow Transplant. 39, 425-429 (2007).
109. Vigouroux S, Morin O, Moreau P et al.. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin. Infect. Dis. 40, e35-e37 (2005).
110. Balasubramanian L, Trifilio SM, Tallman M, Mehta J, Bennett C. Breakthrough zygomycoses in patients receiving antifungal therapy with voriconazole. J. Clin. Oncol. 23(16S), 6664 (2005).
111. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin. Infect. Dis. 40(5), 770-771 (2005).